Afelimomab

DB04956ExperimentalProtein Based Therapies

Afelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.

Mechanism: Pharmacologically active on Tumor necrosis factor
Curator reviewed
Primary indication: Investigated for use/treatment in sepsis and septicemia.Curator reviewed
Code names: LU-54107 · MAK-195F

Resolves to

Compound

UNII6SC756X51VCAS156227-98-4

Clinical / RWD

ATCL04AB03

Targets

P01375TNF

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1,359Drug interactionsStructured to mechanism, not free text

1ATC codeIncluding every combination product, plus 14 drug categories

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Afelimomab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account